Articles tagged with Small Interfering Rna
Small interfering RNA (siRNA) shows potential for treating human diseases by selectively silencing pathological pathways. The review examines siRNA therapeutics in preclinical and clinical trials, challenges faced in siRNA therapy, and the feasibility of combining siRNA with anticancer drugs.
Researchers have discovered a new target and therapy to fight NAFLD, a major health issue affecting 25% of the world population. Using siRNA to silence MCJ protein, they found reduced liver steatosis and fibrosis in preclinical mouse models.
Researchers have identified a new potential agent for treating preeclampsia using small interfering RNA molecules that target the renin-angiotensin-aldosterone system. In animal models, the treatment reduced symptoms of preeclampsia and improved fetal nutrition, suggesting a safe therapeutic option.
Researchers at Lund University have developed a sensitive technique for delivering RNA molecules into cells, potentially opening up new avenues for treating cancer. The study uses cholesterol-linked siRNA and chloroquine to overcome the major obstacle of getting RNA molecules into the cell's cytosol.
Researchers from the University of Cambridge have developed a platform that uses nanoparticles known as metal-organic frameworks to deliver a promising anti-cancer agent, siRNA, to cells. The study shows that MOFs can present a viable platform for delivering potent anti-cancer agents to target specific genes.
Researchers have developed a hydrogel-based carrier that can deliver siRNAs directly to tumors, overcoming the challenge of rapid degradation and limited cellular entry. This innovative technology has the potential to improve the effectiveness of siRNA-based cancer treatments and enable more efficient delivery of biologics.
Scientists at MLU have developed a new method for vaccinating plants against viruses, enabling rapid identification and production of precisely tailored substances. The new method follows the modular principle, allowing for flexible combat against new pests and improving the efficiency of siRNA molecules.
Researchers at Nanjing University have developed a novel RNAi therapy using plant-derived silencing RNAs to inhibit HBsAg expression in mice, showing potential for affordable and effective treatment of chronic hepatitis B. The approach uses methylated short interfering sequences produced by plant endogenous microRNA biogenesis machiner...
Researchers have created a new nanomachine that can deliver specific drugs to parts of the body with tight access barriers, such as pancreatic cancer and brain tumors. The Y-shaped block catiomer is less than one-fifth the size of previous nanoparticles, allowing it to pass through smaller gaps.
Researchers found that low-dose radiation increases the uptake of therapeutic nanoparticles by glioblastomas, allowing for targeted siRNA delivery and improved survival in mouse models. The therapy also activates the immune response at the tumor site, decreasing PD-L1 expression and increasing CD8 T cell recruitment.
Researchers at UMass Medical School developed an siRNA therapy that reduces circulating sFLT1 levels and normalizes blood pressure and proteinuria in pregnant mice. The therapy shows promise as a potential strategy for treating preeclampsia in humans, but further studies are needed to optimize safety and efficacy.
Researchers developed a gene-suppressing drug that, when combined with an over-the-counter gel, accelerated wound healing in mice. The treatment, tested on mice with skin excisions or burns, showed significant improvements in healing outcomes, including regeneration of hair follicles and collagen networks.
Researchers have discovered a new use for green tea's EGCG: delivering therapeutic siRNAs into cells. This breakthrough could lead to treatments for diseases caused by gene misexpression.
Researchers at Salk Institute identify a small family of proteins controlling DNA methylation marks, crucial for gene regulation. This discovery sheds light on epigenetic mechanisms in plants and animals, potentially leading to new strategies for correcting genetic defects associated with diseases like cancer.
Researchers have developed a new method to stabilize small interfering RNAs (siRNAs) by introducing phosphoramidate modifications, which enhances their stability and therapeutic potential. The study shows that the modified siRNAs maintain their gene silencing activity, making them suitable for various therapeutic applications.
A new compound developed by Sylentis can penetrate the retina to treat age-related macular degeneration and diabetic retinopathy with ophthalmic drops. The drug blocks the formation of new blood vessels and has shown efficacy in animal models, offering a promising alternative to painful injections.
Researchers investigated shRNA therapy for Huntington's Disease, identifying novel methods to modulate construct expression and reduce off-target effects. The study proposes two feedback mechanisms to control shRNA expression, inspired by synthetic biology.
A clinical study published in New England Journal of Medicine shows that a single dose of siRNA can significantly reduce LDL cholesterol levels by up to 52.6% after two doses, offering long-lasting protection for high-risk patients.
Scientists have developed a novel combination of an aptamer and siRNAs to target two tumor-dependent genes in prostate cancer cells. This approach shows promise for effective, less toxic gene therapies for various cancers. The strategy uses two 'missiles' to bind to specific proteins, increasing its grip on cancer targets.
Researchers have developed single-stranded silencing RNAs (ss-siRNAs) with improved potency and activity, using inexpensive chemical modification to enhance their therapeutic potential. The study's findings have the potential to democratize gene therapy research, enabling more researchers to explore new treatments.
Researchers at Albert Einstein College of Medicine developed a nanoparticle therapy that reduces fidgetin-like 2 enzyme levels to promote wound healing. The treatment accelerated healing in mice with skin excisions or burns by over twice as much as untreated controls, showing promise for faster recovery from various types of wounds.
Researchers create dye-functionalized nanoparticles that selectively deliver siRNA to liver cells, reducing cholesterol production and offering new hope for personalized therapy approaches. The method uses near-infrared fluorescent dyes as address labels and tracking numbers, allowing for non-invasive monitoring of the transport process.
A novel siRNA-based approach successfully targets and silences the KRAS oncogene, a well-studied but hard-to-halt protein important for cancer development and metastasis. The treatment significantly slows cancer growth and stops metastasis in cultured cells and mice.
A novel RNAi-based therapy has shown promising results in treating anemia by stimulating the liver to produce erythropoietin (EPO). The treatment targets the EGLN1 gene, leading to increased EPO and hemoglobin levels. This breakthrough could provide a safer alternative to current recombinant human EPO treatments.
Researchers discover that mucin concentration in cystic fibrosis airway secretions contributes to decreased mucus clearance and promotes lung infection and inflammation. Meanwhile, an aptamer-based strategy delivers a specific siRNA to tumor cells and Tregs, reducing STAT3 expression and promoting anti-tumor responses.
Researchers have developed tiny, biodegradable nanoparticles that can carry DNA to brain cancer cells in mice, demonstrating potential for targeted treatment. The particles selectively induce death in cancer cells while leaving healthy cells intact, with the possibility of being given to patients during neurosurgery.
Researchers have developed nanoparticles that can efficiently silence target genes in the liver, showing promise for treating cancer and other diseases. The new particles, inspired by lipoproteins, achieve gene knockdown with a small amount of RNA, minimizing side effects in other tissues.
The NIH has made large-scale information on small interfering RNA (siRNA) molecules publicly available, increasing the potential for finding new treatments for diseases. Researchers can now access siRNA sequences targeting over 20,000 human genes, facilitating studies of gene function and disease progression.
Researchers present electronic sutures that monitor surgical incisions, heart-monitoring films, and skin-applied hydration sensors. The symposium explores nanoscale materials for revolutionary healthcare innovations.
Researchers at Sanford-Burnham Medical Research Institute have developed nanoparticles that can deliver small interfering RNA molecules to specific cells, effectively silencing malfunctioning genes. The approach points toward new ways to treat diseases such as cancer and heart disease by using RNA interference.
A new study from MIT sheds light on the nanoparticles' fate, suggesting ways to maximize delivery of short interfering RNA (siRNA) for gene silencing. The researchers found that a protein called Niemann Pick type C1 (NPC1) is crucial for nanoparticle recycling, and disabling it can increase siRNA delivery efficiency.
Researchers have developed nanoparticles that improve siRNA delivery, enabling more efficient silencing of specific genes. The approach shows promise in addressing the challenge of targeted delivery for gene therapies.
Researchers developed a novel approach to deliver cholesterol-conjugated small interfering RNAs (siRNAs) to liver cells using an endosomolytic polymer. The method significantly improves siRNA efficacy for targeted gene silencing, opening new possibilities for disease treatment.
Researchers at UMass Amherst have found a way to deliver bio-active cargo such as proteins and synthetic molecules into naïve T cells using a new synthetic protein transduction domain. This breakthrough enables the study of crucial immune functions and holds great potential for therapeutic applications in the clinic.
The researchers successfully packaged siRNA in a hydrogel complex that can be injected into target tissues, allowing for prolonged control over cell behavior. The technology has the potential to guide stem cells to grow into desired cell types, starve tumors by blocking blood vessel growth, and induce cancer cell death.
Researchers at the University of Illinois have found that small RNAs play a significant role in regulating growth and mediating hybrid vigor in maize. By analyzing small RNA profiles of hybrids, they discovered that differences arise mainly from distinct siRNAs inherited from each parent.
Researchers at the University of Texas at Austin found that maternally inherited small interfering RNAs control seed development, leading to smaller seeds. This discovery has significant implications for agriculture and understanding plant evolution.
Researchers at MIT have developed a novel RNA interference method that delivers short interfering RNA (siRNA) using microspheres, overcoming the challenge of efficient delivery in the body. The new system shows promise for targeting specific genes in tumors and other diseased cells.
Scientists at Virginia Tech have discovered a novel antiviral immune pathway in culicine mosquitoes, which produces virus-derived small RNAs similar to piwi-interacting RNAs. This finding suggests a robust immune system, but understanding how viruses overcome it remains an open challenge.
New research by University of Kentucky investigators found that short-interfering RNAs can induce retinal degeneration via TLR3 and IRF3. This discovery highlights the need for caution when designing or using siRNAs intended for eye treatment.
Researchers at Massachusetts General Hospital have developed a novel technique using RNA interference to block inflammation in animal models of several disorders. The technique targets specific inflammatory cells that contribute to conditions such as heart disease and cancer, reducing damage and improving survival rates.
Researchers at Ohio State University designed a nanocarrier that maximizes gene silencing by targeting equivalent highways for entry into cells. The carrier, called SPANosome, reduces protein production by 95% compared to traditional carriers.
Researchers at NIH have demonstrated how to reactivate immune cells exhausted by chronic HIV using siRNA-based approach. This breakthrough may lead to improved human antibody responses against HIV and other pathogens.
Researchers have developed a novel, topically-applied molecular microbicide that uses RNA interference (RNAi) to prevent HIV transmission. The microbicide was tested in mice and found to provide long-lasting protection against HIV infection, opening the door to developing an intravaginal microbicide for women's protection.
A novel approach to delivering small bits of genetic material into the body has been developed by researchers at Georgia Institute of Technology and Emory University. The thioketal nanoparticles successfully targeted inflamed intestinal tissues, reducing inflammation and promoting healing.
A groundbreaking study has shown that a novel treatment using small interfering RNAs can protect monkeys from lethal Ebola virus infection after exposure. The treatment was found to be well-tolerated and offered complete protection in some cases, paving the way for further research and potential human trials.
Scientists developed a multistage nanovector system to deliver siRNA, significantly lengthening the therapeutic effects of treatment in mouse models of ovarian cancer. The system provides sustained delivery of siRNA for up to three weeks, targeting the EphA2 oncoprotein.
Researchers demonstrate targeted nanoparticle delivery of siRNA to cancer cells, turning off an important gene using RNA interference. The study opens the door for future genetic therapies that can attack cancer and other diseases at a molecular level.
Researchers at CSHL and Mexico's National Polytechnic Institute successfully inhibited asexual reproduction in a sexually reproducing plant by silencing transposons. This breakthrough could lead to the creation of genetically identical seeds with valuable parental traits, greatly increasing crop yields.
Using hydrogels to deliver small interfering RNA (siRNA) into cancer cells has been shown to effectively target and kill them. The technique inhibits EGFR growth, increasing programmed cell death and enhancing the effects of traditional chemotherapy.
Researchers at University of Iowa have modified siRNA to be injectable into the bloodstream, targeting specific genes overexpressed in cancer cells. The new compound triggers tumor regression without affecting normal tissues.
The development of siRNA drugs is hindered by a strong immune response that can cause toxic side effects. Researchers are exploring mechanisms for inducing this response and strategies for minimizing its effects.
Researchers at UC San Diego School of Medicine have developed an efficient system for delivering siRNA into primary cells, overcoming a major hurdle in RNAi-based cancer therapy. The PTD-DRBD fusion protein enables targeted gene silencing in various cell types without toxicity or immune responses.
Researchers have developed a four-in-one agent that can detect, target, and disable tumor cells while also making them visible through MRI and microscopic imaging. The agent uses siRNAs to suppress specific genes in cancer cells, providing a new approach to targeted gene suppression in cancer treatment.
Researchers at Yale University have developed a novel approach to deliver small interfering RNA (siRNA) molecules using biodegradable nanoparticles, achieving sustained release and effective knockdown of gene activity. This breakthrough holds promise for the treatment of sexually transmitted diseases (STDs), particularly HPV and HIV.
A team of scientists has identified a crucial requirement for heterochromatin formation, showing that the strength of Chp1's binding to methylated chromatin is essential. This breakthrough reveals a key mechanism in regulating gene expression and genomic stability.
Researchers have designed tiny RNA molecules that can reduce production of the damaging Huntingtin protein in nearly half of people with the disease. An additional set of four small interfering RNAs may benefit an additional 25 percent of patients.
A new study by Dr. Jayakrishna Ambati and colleagues found that the siRNA treatment is toxic to both blood and lymphatic endothelial cells, with potential applications in cornea transplantation and treatment of lymphatic diseases.
Scientists at UB's Institute for Lasers, Photonics and Biophotonics have developed a stable nanoparticle that delivers short RNA molecules to silence a gene critical in many kinds of drug addiction. The approach also shows promise for treating Parkinson's disease, cancer, and other neurologic and psychiatric disorders.
Biologists at Washington University in St. Louis have found that plant enzymes Pol IV and V are specialized forms of RNA Polymerase II, essential for decoding genetic information in eukaryotes. The discovery sheds light on the evolution of RNA polymerases and their role in gene silencing.